AR and posterior cortical atrophy: For these experiments, we performed immunofluorescence using two patient-derived xenograft (PDX) models of prostate cancer (PCa) obtained from the Movember Global Action Plan 1: a primary prostate adenocarcinoma (MDA PCa 173-2, androgen naïve, Gleason score 3 + 4) and a bone metastatic (met) tumor (MDA PCa 183-A, Androgen Receptor positive) [53].